LBPH241220C80000
- 0.00
- 0.000.00%
Longboard Pharmaceuticals Newsroom
Hold Rating for Longboard Pharmaceuticals Amidst Acquisition Uncertainty and Speculative Risks
Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Hold Rating
Longboard Pharmaceuticals Cut to Neutral From Buy by HC Wainwright & Co.
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Cuts Target Price to $60
Truist Financial Upgrades Longboard Pharmaceuticals(LBPH.US) to Buy Rating, Maintains Target Price $60
Strong Valuation and Strategic Acquisition Drive Buy Rating for Longboard Pharmaceuticals
Longboard Pharmaceuticals Price Target Maintained With a $60.00/Share by Truist Securities
A Quick Look at Today's Ratings for Longboard Pharmaceuticals(LBPH.US), With a Forecast Between $60 to $60
Baird Downgrades Longboard Pharmaceuticals to Neutral From Outperform, Price Target Is $60
Longboard Pharmaceuticals Cut to Neutral From Overweight by Cantor Fitzgerald
Longboard Pharmaceuticals Analyst Ratings
H.C. Wainwright Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $80
A Quick Look at Today's Ratings for Longboard Pharmaceuticals(LBPH.US), With a Forecast Between $44 to $80
Longboard Pharmaceuticals Is Maintained at Outperform by Wedbush
Wedbush Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Raises Target Price to $44
Truist Financial Maintains Longboard Pharmaceuticals(LBPH.US) With Buy Rating
Truist Financial Sticks to Its Buy Rating for Longboard Pharmaceuticals (LBPH)
Longboard Pharmaceuticals Price Target Maintained With a $90.00/Share by Cantor Fitzgerald
Longboard Pharmaceuticals Analyst Ratings
Truist Financial Initiates Longboard Pharmaceuticals(LBPH.US) With Buy Rating, Announces Target Price $60